Hindustan Bio Sciences Reports Mixed Performance in Q2 2024 Financial Results

Hindustan Bio Sciences, a microcap pharmaceutical company, recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Sell' call by MarketsMOJO. According to the financial report, Hindustan Bio Sciences has seen a flat performance in the second quarter of the fiscal year 2024-2025. The company's score has fallen from 7 to 0 in the last three months. However, there are some positive aspects to the company's financials. One of the highlights is the Debtors Turnover Ratio, which has been consistently growing each half year and is currently at its highest at 22.40 times. This indicates that the company has been able to settle its debtors faster. Additionally, the Profit After Tax (PAT) for the nine-month period is higher at Rs 0.07 crore compared to the previous 12-month period. This shows that the company has already surpassed its sales from the previous year. On the other hand, there are some areas of concern for Hindustan Bio Sciences. The Operating Profit (PBDIT) for the quarter is at its lowest in the last five quarters at Rs -0.05 crore. The trend for near-term operating profit is also negative. Similarly, the Profit Before Tax less Other Income (PBT) for the quarter is also at its lowest in the last five quarters, with a negative trend in the near term. The company's Earnings per Share (EPS) for the quarter is also at its lowest in the last five quarters, indicating a decline in profitability and lower earnings for shareholders. Overall, Hindustan Bio Sciences has shown a mixed performance in the recent quarter, with some positive and negative aspects. Investors are advised to carefully analyze the company's financials before making any investment decisions.